NDA 021323 · Abbvie
Lexapro
Escitalopram Oxalate · Oral
Last checked: Nov 20, 2026Latest source record: Apr 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Aug 14, 2002
Approved uses
7
Original approval plus efficacy supplements
Registered trials
484
106 Phase 3, 29 recruiting
FAERS reports
127,231
84,617 serious, 10,109 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior s in pediatric and young adult patients in short-term studies . Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions ( 5.1 )] . Lexapro is not approved for use in pediatric patients less than 7 years of age [ s ee Use in Specific Populations ( 8.4 )] . WARNING: SUICIDAL THOUGHTS AN D BEHAVIORS See full prescribing information for complete boxed warning. Increased risk of suicidal thoughts and behavior in pediatric and you ng adult patients taking antidepressants . Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Lexapro is not approved for use in pediatric patients less than 7 years of age (...
What it is approved for
From the label in effect Oct 1, 2023.
Lexapro is indicated for the treatment of: • major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. • generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older. Lexapro is a selective serotonin reuptake inhibitor (SSRI) indicated for the: treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older ( 1 ) treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years and older ( 1 )
Mechanism: The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 12, 2023 Supplement 55 · Efficacy LetterLabelMedication Guide
- Mar 19, 2009 Supplement 30 · Efficacy ReviewLetterLabel
- Mar 19, 2009 Supplement 31 · Efficacy LetterReviewLabel
- Dec 18, 2003 Supplement 3 · Efficacy LabelLetterReview
- Dec 18, 2003 Supplement 7 · Efficacy LabelReviewLetter
- Aug 29, 2002 Supplement 1 · Efficacy ReviewLetterLabel
- Aug 14, 2002 Original approval · Type 3 - New Dosage Form ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
3 products under this application
- LEXAPRO · ESCITALOPRAM OXALATE EQ 20MG BASE · TABLET, ORAL · Prescription · TE AB
- LEXAPRO · ESCITALOPRAM OXALATE EQ 5MG BASE · TABLET, ORAL · Prescription · TE AB
- LEXAPRO · ESCITALOPRAM OXALATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Escitalopram Oxalate" as an intervention, any sponsor and status, largest first.
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT05480150 · 10,000 participants (planned) · Start Nov 1, 2021 · Primary completion Dec 31, 2026
Drug: Escitalopram Oxalate Tablets; Quetiapine Fumarate Tablets and 1 more · For: Major Depressive Disorder; Bipolar Disorder, Mixed; Affective; Disorder, Organic
Sites: Hangzhou, China
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- International Study to Predict Optimised Treatment - in DepressionPivotal-lookingStatus unknown
BRC Operations Pty. Ltd.Industry
NCT00693849 · 2,688 participants (planned) · Start Sep 2008 · Primary completion Dec 2019
Drug: Escitalopram; Sertraline and 1 more · For: Major Depressive Disorder
Sites: Colton, California; Mission Viejo, California; Stanford, California · 20 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Improving Outcomes in Depression in Primary Care in a Low Resource SettingPivotal-lookingActive, not recruiting
Harvard Medical School (HMS and HSDM)Academic, hospital or other
NCT05944926 · 1,500 participants (planned) · Start Mar 18, 2024 · Primary completion Apr 10, 2026
Drug: Antidepressant medication (fluoxetine) · For: Depression; Depressive Disorder
Sites: Bhopal, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea8,649
- fatigue8,646
- drug ineffective8,210
- headache6,442
- diarrhoea6,305
- anxiety6,260
- depression5,814
- dizziness5,723
- off label use5,573
- pain5,306
- fall5,050
- vomiting4,742
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,788 |
| 2005 | 2,181 |
| 2006 | 2,103 |
| 2007 | 2,484 |
| 2008 | 2,407 |
| 2009 | 3,301 |
| 2010 | 4,363 |
| 2011 | 4,140 |
| 2012 | 4,641 |
| 2013 | 3,839 |
| 2014 | 4,290 |
| 2015 | 6,534 |
| 2016 | 8,096 |
| 2017 | 7,350 |
| 2018 | 8,674 |
| 2019 | 8,985 |
| 2020 | 8,696 |
| 2021 | 7,186 |
| 2022 | 7,544 |
| 2023 | 7,524 |
| 2024 | 7,739 |
| 2025 | 7,551 |
| 2026 | 5,814 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lexapro (Escitalopram Oxalate)
2024 spending
$17.6M
Beneficiaries
4,182
20,281 claims
Per beneficiary
$4,209
$14.04 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $20,941,265 |
| 2021 | $20,061,718 |
| 2022 | $19,479,267 |
| 2023 | $18,746,937 |
| 2024 | $17,602,517 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
Milosavljevic F, Bukvic N, Pavlovic Z, et al. · JAMA Psychiatry 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Quetiapine combined with escitalopram in the treatment of bipolar depression.
Zhang P, Huang J, Xiong Z, et al. · Int J Psychiatry Med 2025 · Randomized Controlled Trial
- Magnetic Resonance Imaging to Evaluate the Recovery Effects of Cerebral Nerve Function in Comprehensive Treatment of Poststroke Depression by Intelligent Algorithm-Based Hyperbaric Oxygen Therapy.
Yuan C, Zhang L, Hao Y, et al. · Comput Intell Neurosci 2022 · Randomized Controlled Trial
- Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique.
Rausch JL, Corley KM, Hobby HM · J Clin Psychopharmacol 2004 · Clinical Trial, Randomized Controlled Trial
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2004 · Clinical Trial
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.